Peripheral neuropathy with microtubule-targeting agents: Occurrence and management approach

Clinical Breast Cancer

Volumn 11, Issue 2, 2011, Pages 73-81

  Carlson, Karen ^a   Ocean, Allyson J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adverse events; Ixabepilone; Management; Microtubule targeting agents; Peripheral neuropathy; Taxanes

Indexed keywords

AMIFOSTINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CALCIUM DERIVATIVE; CAPECITABINE; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; EPOTHILONE B; GLUTAMINE; GLUTATHIONE; IXABEPILONE; MAGNESIUM DERIVATIVE; MICROTUBULE TARGETING AGENT; NAVELBINE; OXALIPLATIN; PACLITAXEL; SAGOPILONE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VINCRISTINE; VINFLUNINE;

BREAST CANCER; CELL VACUOLE; CEREBRAL BLINDNESS; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONSTIPATION; DIPLOPIA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; FACIAL NERVE PARALYSIS; HEARING LOSS; HUMAN; INCIDENCE; JAW PAIN; MEGACOLON; MICROTUBULE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; MYALGIA; MYOPATHY; NERVE CELL; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OCULOMOTOR NERVE DYSFUNCTION; OPHTHALMOPLEGIA; OVARY CANCER; PARALYTIC ILEUS; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PTOSIS; REVIEW; RISK FACTOR; SENSORY NEUROPATHY; SOLID TUMOR; VOCAL CORD PARALYSIS; WEAKNESS;

EID: 80051720415     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2011.03.006     Document Type: Review

References (90)

1. Morris PG, Fornier MN. Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 2008;14:7167-72.
2. Cortes J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 2007;12:271-80. (Pubitemid 46556793)
3. Lee FY, Borzilleri R, Fairchild CR, et al. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol 2008;63:157-66.
4. Lee FY, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 2009;63:201-12.
5. Vahdat L. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Oncologist 2008;13:214-21. (Pubitemid 351679896)
6. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule- stabilizing agents. J Clin Oncol 2006;24:1633-42. (Pubitemid 46638788)
7. Swain SM, Arezzo JC. Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 2008;6:455-67.
8. Argyriou AA, Koltzenburg M, Polychronopoulos P, et al. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 2008;66:218-28.
9. Cavaletti G, Cavalletti E, Oggioni N, et al. Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. Neurotoxicology 2000;21:389-93.
10. Cavaletti G, Tredici G, Braga M, et al. Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol 1995;133:64-72.
11. Sahenk Z, Barohn R, New P, et al. Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch Neurol 1994;51:726-9. (Pubitemid 24201893)
12. Polomano RC, Mannes AJ, Clark US, et al. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 2001;94:293-304. (Pubitemid 33145399)
13. Flatters S J L, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 2006;122:245-57. (Pubitemid 43729476)
14. Siau C, Xiao W, Bennett GJ. Paclitaxel-and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp Neurol 2006;201:507-14. (Pubitemid 44344243)
15. Lauria G, Lombardi R, Borgna M, et al. Intraepidermal nerve fiber density in rat foot pad: neuropathologic-neurophysiologic correlation. J Peripher Nerv Syst 2005;10:202-8. (Pubitemid 40984894)
16. Peters CM, Jimenez-Andrade JM, Kuskowski MA, et al. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res 2007;1168:46-59. (Pubitemid 47320623)
17. Persohn E, Canta A, Schoepfer S, et al. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer 2005;41:1460-6. (Pubitemid 40826471)
18. Chiorazzi A, Nicolini G, Canta A, et al. Experimental epothilone B neurotoxicity: results of in vitro and in vivo studies. Neurobiol Dis 2009;35:270-7.
19. Latiff ZA, Kamal NA, Jahendran J, et al. Vincristine-induced vocal cord palsy: case report and review of the literature. J Pediatr Hematol Oncol 2010;32:407-10.
20. Tuxen MK, Hansen SW. Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev 1994;20:191-214. (Pubitemid 24118030)
21. Kuruvilla G, Perry S, Wilson B, et al. The natural history of vincristine-induced laryngeal paralysis in children. Arch Otolaryngol Head Neck Surg 2009;135:101-5.
22. Argyriou AA, Polychronopoulos P, Koutras A, et al. Peripheral neuropathy induced by administration of cisplatin and paclitaxel-based chemotherapy. Could it be predicted? Support Care Cancer 2005;13:647-51. (Pubitemid 41040187)
23. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14. (Pubitemid 11167383)
24. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55. (Pubitemid 13149996)
25. National Cancer Institute Common Terminology Criteria for Adverse Events Criteria (NCI CTCAE) for Peripheral Neuropathy Version 4.0. Available at: http://www.evs.nci.nih.gov/ftp1/CTCAE/About.html. Accessed: August 06, 2010.
26. Postma TJ, Heimans JJ. Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 2000;11:509-13. (Pubitemid 30431370)
27. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2010;15:79-92.
28. England JD, Gronseth GS, Franklin G, et al. Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation 2009;1:14-22.
29. Griffin JW, McArthur JC, Polydefkis M. Assessment of cutaneous innervation by skin biopsies. Curr Opin Neurol 2001;14:655-9. (Pubitemid 32964587)
30. Postma TJ, Heimans JJ, Muller MJ, et al. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998;9:739-44. (Pubitemid 28394160)
31. Cavaletti G, Frigeni B, Lanzani F, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 2007;12:210-5. (Pubitemid 47404378)
32. Cavaletti G, Jann S, Pace A, et al. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 2006;11:135-41. (Pubitemid 43894080)
33. Argyriou AA, Polychronopoulos P, Iconomou G, et al. Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies. J Neurol 2005;252:1459-64. (Pubitemid 41803834)
34. Argyriou AA, Polychronopoulos P, Koutras A, et al. Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy. Eur J Cancer Care (Engl) 2007;16:231-7.
35. du Bois A, Luck HJ, Meier W, et al. Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320-9.
36. Chaudhry V, Rowinsky EK, Sartorius SE, et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 1994;35:304-11. (Pubitemid 24089653)
37. Viens P, Petit T, Yovine A, et al. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Ann Oncol 2006;17:429-36. (Pubitemid 43329579)
38. Jamieson SM, Liu J, Hsu T, et al. Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity. Br J Cancer 2003;88:1942-7. (Pubitemid 36829672)
39. Chaudhry V, Chaudhry M, Crawford TO, et al. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003;60:337-40. (Pubitemid 36152036)
40. Akerley W, Herndon JE, Egorin MJ, et al. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer 2003;97:2480-6. (Pubitemid 36542487)
41. Argyriou AA, Polychronopoulos P, Koutras A, et al. Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support Care Cancer 2006;14:223-9. (Pubitemid 43247926)
42. Stubblefield MD, Burstein HJ, Burton AW, et al. NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw 2009;7(suppl 5):1-26.
43. Verstappen CC, Koeppen S, Heimans JJ, et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 2005;64:1076-7. (Pubitemid 40388469)
44. Zelek L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001;92:2267-72. (Pubitemid 33029069)
45. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al. Clinical toxicities encountered by paclitaxel (Taxol). Semin Oncol 1993;20(suppl 3):1-15. (Pubitemid 23239390)
46. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005;23:5542-51.
47. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803. (Pubitemid 46657376)
48. Winer EP, Berry DA, Woolf S, et al. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial. J Clin Oncol 2004;22:2061-8. (Pubitemid 41095138)
49. Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858-67. (Pubitemid 26185461)
50. Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995;13:2575-81.
51. Seidman AD, Berry D, Cirrincione C, et al. CALGB 9840: phase III study of weekly paclitaxel via 1-hour infusion versus standard 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 2004;22(14 S):(Abstract 512).
52. Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 1999;17:3403-11. (Pubitemid 29517907)
53. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006;7:1041-53. (Pubitemid 43949942)
54. Mielke S, Sparreboom A, Steinberg SM, et al. Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 2005;11:4843-50. (Pubitemid 41557204)
55. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:1663-71. (Pubitemid 351549913)
56. IXEMPRA (ixabepilone) for injection [prescribing information]. Princeton, NJ, Bristol-Myers Squibb Company 2010. http://www.ixempra.com/Accessed March 14, 2011.
57. Baselga J, Gianni L, Llombart A, et al. Predicting response to ixabepilone: genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer. Breast Cancer Res Treat 2005;94(suppl 1):31-2. (Abstract 305).
58. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone Banalog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25:3399-406. (Pubitemid 47310875)
59. Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25:3415-20. (Pubitemid 47310877)
60. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone analog, in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407-14. (Pubitemid 47310876)
61. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-7. (Pubitemid 350232252)
62. Sparano JA, Vrdoljak E, Rixe O, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010;28:3256-63.
63. Perez EA, Pivot X, Vrdoljak E, et al. Aprospective characterization of the resolution of ixabepilone induced peripheral neuropathy: data from a large registrational program in patients with metastatic breast cancer. Cancer Res 2009;69(suppl 2):401-2 (Abstract 6140).
64. Smith JW II, Vukelja SJ, Rabe AC, et al. Preliminary toxicity results of a phase II randomized trial of weekly or every 3-week ixabepilone in metastatic breast cancer (MBC). Cancer Res 2009;69(24 suppl 3):856s (Abstract 6099).
65. Rugo HS, Campone M, Amadori D, et al. Randomized study of weekly vs every 3 week ixabepilone plus bevacizumab (ixa/bev) vs paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): final results. J Clin Oncol 2010;28(15 S):123S (Abstract 1040).
66. Vahdat LT, Thomas E, Roche H, et al. Ixabepilone (Ixa)-associated peripheral neuropathy (PN): retrospective review of data from phase II and III clinical trials. Ann Oncol 2010;21(suppl 8):viii109 (Abstract 320P).
67. Rubin EH, Rothermel J, Tesfaye F, et al. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumours. JClin Oncol 2005;23:9120-9.
68. Østerlind K, Sanchez JM, Zatloukal P, et al. Phase I/II dose escalation trial of patupilone every 3 weeks in patients with non-small cell lung cancer. J Clin Oncol 2005;23:647s (Abstract 7110).
69. Schmid P, Kiewe P, Possinger K, et al. Phase I study of the novel fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Ann Oncol 2010;21:633-9.
70. Hilkens PH, Verweij J, Vecht CJ, et al. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann Oncol 1997;8:187-90. (Pubitemid 27112888)
71. Ocean AJ, Vahdat LT. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 2004;12:619-25. (Pubitemid 39280311)
72. Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009;27:127-45.
73. Vahdat L, Papadopoulos K, Lange D, et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 2001;7:1192-7. (Pubitemid 32708669)
74. Stubblefield MD, Vahdat LT, Balmaceda CM, et al. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electro-physiologic study. Clin Oncol (R Coll Radiol) 2005;17:271-6. (Pubitemid 40716452)
75. Wang WS, Lin JK, Lin TC, et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 2007;12:312-9.
76. Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002;20:3478-83.
77. Sarris AH, Hagemeister F, Romaguera J, et al. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol 2000;11:69-72. (Pubitemid 30084582)
78. Vogel C, O'Rourke M, Winer E, et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 1999;10:397-402. (Pubitemid 29236416)
79. Fumoleau P, Delgado FM, Delozier T, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993;11:1245-52. (Pubitemid 23199126)
80. Campone M, Cortes-Funes H, Vorobiof D, et al. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br J Cancer 2006;95:1161-6. (Pubitemid 44658478)
81. Blum JL, Dees EC, Chacko A, et al. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2006;24:4384-90. (Pubitemid 46630975)
82. Perez EA, Vogel CL, Irwin DH, et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001;19:4216-23. (Pubitemid 33081639)
83. Miller KD, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005;94(suppl 1):S6 (Abstract 3).
84. O'Shaughnessy JA, Blum JL, Sandbach JF, et al. Weekly nanoparticle albumin paclitaxel (Abraxane) results in long-term disease control in patients with taxane-refractory metastatic breast cancer. Breast Cancer Res Treat 2004;88:S65 (Abstract 1070).
85. Alba E, Martin M, Ramos M, et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 2004;22:2587-93. (Pubitemid 41103745)
86. Bonneterre J, Roche H, Monnier A, et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 2002;87:1210-5. (Pubitemid 36009124)
87. Tabernero J, Climent MA, Lluch A, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004;15:1358-65. (Pubitemid 39295024)
88. Eniu A, Palmieri FM, Perez EA. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 2005;10:665-85. (Pubitemid 41567278)
89. Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005;23:2726-34. (Pubitemid 46179462)
90. Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007;25:3421-7. (Pubitemid 47310878)